SecBot SecBot
PRE-MARKET · Mon · Nov 9 · 2026 · 07:36 ET ·REGIMEELEVATED

Chip sector recovery bounce meets midterm policy uncertainty, VIX eases to 23.49 as markets look past the Democratic sweep sell-off and await October CPI data.

SecBot Research
01Executive summary
  • US equity futures are pointing to a higher open after Friday's mixed session, with the Nasdaq (+1.09%) and S&P 500 (+0.31%) gaining while the Dow (-0.46%) lagged.
  • Chip stocks are leading the recovery bounce, AMD surged +16.7% in pre-market after an Oppenheimer upgrade, while INTC rose +7.9% on Friday following CEO insider buying.
  • Nvidia (NVDA) is under pressure pre-market (-5.9%) after reports the board opened a probe into CEO Jensen Huang, adding governance overhang to a stock already down 23% from its 52-week high.
  • European and Asian markets rallied overnight, Euro Stoxx 50 +1.2%, Nikkei +2.3%, as global equities stabilise following last week's Democratic midterm sweep.
  • Oil dropped -2.9% to $88.23 on demand concerns, while gold rose +1.1% to $4,121, reflecting persistent safe-haven flows.
  • October CPI data due this week is the next major macro catalyst, with Fed speakers likely to reinforce a cautious tone on rate cuts.
02Market snapshot
S&P 500
7,376.86
▲ +0.31% +23.13
30D -5.45%
Nasdaq
24,579.43
▲ +1.09% +264.43
30D -10.75%
Dow Jones
51,285.73
▼ -0.46% -237.33
30D +0.21%
Russell 2000
2,754.11
▲ +0.89% +24.22
30D -1.40%
VIX
25.64
▼ -9.01% -2.54
30D +70.03%
03Sector & breadth
Leaders
Technology (XLK)
+1.45%
Communication Services (XLC)
+0.43%
Industrials (XLI)
+0.12%
Laggards
Consumer Staples (XLP)
-1.28%
Materials (XLB)
-0.73%
Real Estate (XLRE)
-0.68%
04ETF flows
Inflows
SPY SPDR S&P 500 ETF Trust
+$5.14B
QQQ Invesco QQQ Trust
+$3.94B
SOXX iShares Semiconductor ETF
+$1.01B
IEF iShares 7-10 Year Treasury Bond ETF
+$669.4M
TLT iShares 20+ Year Treasury Bond ETF
+$409.0M
Outflows
IGV iShares Expanded Tech-Software ETF
-$396.5M
XLF Financial Select Sector SPDR
-$370.2M
DIA SPDR Dow Jones Industrial Average ETF
-$258.5M
COPX Global X Copper Miners ETF
-$237.8M
XLY Consumer Discretionary Select SPDR
-$184.6M
05Biggest movers
Gainers
AMD ▲ +16.7%
Advanced Micro Devices
Oppenheimer upgrade to Outperform with $600 PT; chip sector recovery bounce after midterm sell-off
INTC ▲ +7.9%
Intel Corp
CEO Lip-Bu Tan's family trust purchased $9.7M in shares (discretionary, not 10b5-1); chip sector stabilising
NSC ▲ +7.1%
Norfolk Southern
Q3 earnings beat; raised full-year capital spending guidance
TSLA ▲ +4.2%
Tesla Inc
Recovery bounce after midterm-driven sell-off; Cathie Wood buying tech dip
Losers
NVDA ▼ -5.9%
Nvidia Corp
Board opened probe into CEO Jensen Huang; governance overhang compounds existing AI demand concerns
CRM ▼ -3.9%
Salesforce Inc
Continued tech rotation pressure; midterm policy uncertainty weighing on enterprise software
NFLX ▼ -3.3%
Netflix Inc
Sector rotation out of growth; streaming competition concerns resurface
06Key drivers
  1. 01 Democrats swept Congress in the Nov 4 midterms, triggering a sharp Nov 5 sell-off (S&P -4.4%) that is now seeing a measured recovery.
  2. 02 Nvidia board probe into CEO Jensen Huang, governance risk adding to existing headwinds from AI capex scrutiny and midterm policy uncertainty.
  3. 03 October CPI report due this week is the next major macro catalyst; Fed's Daly signalled higher rates may still be needed.
  4. 04 Oil dropping to $88.23 (-2.9%) on demand concerns, partially offsetting inflation fears but pressuring energy equities.
  5. 05 Gold at $4,121 (+1.1%) and DXY at 101.88 (-0.4%) reflect continued safe-haven demand and dollar weakness.
  6. 06 European and Asian markets rallied overnight (STOXX +1.2%, Nikkei +2.3%) as global risk appetite stabilises.
  7. 07 Oppenheimer upgraded AMD to Outperform with $600 PT, adding positive catalyst to the chip sector recovery trade.
07Technical analysis
S&P 500
S&P 500 closed at 7,376.86, holding above the 200-day SMA (7,325.05) by +0.7%. Near-term support at 7,357.74 (Friday's low), with resistance at 7,554.40. RSI at 35.11 remains in bearish territory but not oversold. The index is below both the 21-day (7,665.12) and 50-day (7,679.45) SMAs, confirming the short-term downtrend.
Nasdaq
Nasdaq closed at 24,579.42 with a technical score of -21.24 (sell). RSI at 33.86 is approaching oversold. Support at 24,372.05 (Friday's low), resistance at 24,899.37. The index is below all three key SMAs (21d: 26,136.72, 50d: 26,457.82, 200d: 25,098.28).
VIX
VIX eased to 23.49 pre-market from Friday's close of 25.64, a -8.4% decline. The VIX remains well above its 21-day SMA (19.05) and 50-day SMA (17.09), indicating elevated anxiety. A move below 21.83 would signal further stabilisation; resistance at 23.93 and 28.25.
08Cross-market
US Treasuries
10-year yield 4.86% (+2bp from Friday's 4.84%), 2-year 4.46%, 2s10s spread +35bp (normal curve).
FX
DXY 101.88 (-0.4%), EUR/USD testing 1.1163 pivot, GBP/USD above 1.3373.
Commodities
Oil $88.23 (-2.9%) on demand concerns; Gold $4,121 (+1.1%) safe-haven bid; Copper $6.26/lb (-0.3%).
Europe / Asia
Euro Stoxx 50 +1.2%, FTSE 100 +0.7%, Nikkei 225 +2.3%, Hang Seng -0.1%. Broad risk-on tone in Asia and Europe.
Other
Bitcoin $74,722 (-1.5%), holding below $75K amid crypto credit stress and Binance hack overhang.
09Upcoming calendar
Economic 2
October CPI Report (Wednesday Nov 12)
Fed speakers, multiple appearances this week
Earnings 2
AAON AAON Inc. AMC
Nov 9, 2026
Q3 results after the close; HVAC demand barometer
AMG Affiliated Managers Group BMO
Nov 9, 2026
Q3 earnings before the open; asset management fee revenue read
Biotech catalysts 5
NVCR NovoCure Ltd
PMA
CRL / Not Approvable Letter · Nov 9, 2026
Brain metastases from NSCLC
FDA issued Not Approvable Letter for Optune Mya due to uncertainty around clinical benefit, negative catalyst
NRXP NRX Pharmaceuticals
ANDA
PDUFA · Nov 10, 2026
Drug shortage product (NRX-100)
GDUFA goal date after amendment reclassification; binary catalyst for micro-cap
SMMT Summit Therapeutics
BLA
PDUFA · Nov 14, 2026
EGFR-mutated NSCLC (ivonescimab)
Franchise-defining PDUFA for ivonescimab in first-line EGFR-mutated NSCLC; $10B+ peak sales opportunity
CYTK Cytokinetics
sNDA
PDUFA · Nov 14, 2026
Obstructive HCM (aficamten)
sNDA for aficamten based on MAPLE-HCM data; pivotal for Cytokinetics' commercial future
BTAI BioXcel Therapeutics
sNDA
PDUFA · Nov 14, 2026
Acute agitation (IGALMI at-home)
sNDA for at-home use label expansion; could dramatically expand addressable market
10 Stocks in focus Quotes as of 07:26 ET

Names in focus based on expected market-moving catalysts and technical setups. Descriptive commentary only, not investment advice or a recommendation to buy or sell any security.

AMD
Advanced Micro Devices
▲UPSIDE High PROB NEWS
$469.37 ▲ +4.53% 24h
Price at report release
Oppenheimer upgraded AMD to Outperform with a $600 price target this morning, adding positive analyst momentum to a chip sector already recovering from last week's midterm-driven sell-off. With 50 of 60 analysts at Buy/Strong Buy and a mean target of $659.77 implying 46.9% upside from Friday's close, the setup points to continued recovery as the market looks past the Democratic sweep.
Resistance
$564.75+20.3% ↑
$523.22+11.5% ↑
$491.12+4.6% ↑
$469.22−0.0% ↑
▶$469.37Now
Support
$441.61−5.9% ↓
$393.36−16.2% ↓
NVDA
Nvidia Corp
▼DOWNSIDE High PROB NEWS
$175.65 ▼ -5.89% 24h
Price at report release
Reports that Nvidia's board opened a probe into CEO Jensen Huang introduce a significant corporate governance overhang on a stock already down 23% from its 52-week high. The technical structure is deteriorating, RSI at 30.76, MACD bearish, and price below the lower Bollinger Band ($188.34). Watching for a break below $174.76 support, which would open a path toward the 52-week low at $164.27.
Resistance
$230.81+31.4% ↑
$215.27+22.6% ↑
$200.29+14.0% ↑
$190.57+8.5% ↑
▶$175.65Now
Support
$174.76−0.5% ↓
IMVT
Immunovant Inc.
▲UPSIDE High PROB BIOTECH
$34.25 ▲ +12.19% 24h
Price at report release
Immunovant reported positive Phase 2 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with the 600mg dose meeting the primary endpoint (ACR20 at Week 28: 92.5% vs 75.6% placebo, p=0.0139). The stock is up 12.2% pre-market with volume 2x average. The favourable safety profile and clear efficacy signal support further upside toward the next resistance at $34.60, with the 52-week high at $45.42 as the longer-term target.
Resistance
$38.97+13.8% ↑
$36.28+5.9% ↑
$34.60+1.0% ↑
$32.88−4.0% ↑
▶$34.25Now
Support
$30.28−11.6% ↓
$26.99−21.2% ↓
$25.41−25.8% ↓
11Outlook
The pre-market tone is constructive after Friday's mixed close, with European and Asian bourses rallying and US futures pointing higher. The chip sector is leading the recovery bounce, but the Nvidia board probe introduces a wild card that could pressure the broader semiconductor complex. The VIX easing to 23.49 from Friday's 25.64 close suggests fear is abating, but at 23.49 it remains elevated enough to keep positioning defensive. October CPI data on Wednesday is the week's defining risk event, a hot print would reinforce the Fed's higher-for-longer narrative and could re-ignite the sell-off. The key level to watch is S&P 7,357.74 support; a break below that would signal the recovery attempt has failed.
Important disclosures

This report is for informational and educational purposes only. It is not investment advice, a research report within the meaning of applicable securities regulations, or a recommendation, solicitation, or offer to buy or sell any security.

References to expected price moves, support and resistance levels, or names "in focus" are descriptive observations about market conditions and expected behaviour, not directives to take a position. SecBot is not a registered investment adviser, broker-dealer, or financial planner. Past performance does not indicate future results. Any investment decisions are solely your own and you should consult a qualified financial professional who understands your individual circumstances before acting on any information herein.

SecBot and its affiliates may hold positions in securities mentioned. Figures are sourced from third-party data providers and may contain errors; readers should independently verify before relying on any specific number.